Evidence map›Paper›PMID 38303830›Full record

ArticleJournal of dental sciences2024

Serpin peptidase inhibitor, clade E, member 2 is associated with malignant progression and clinical prognosis in oral squamous cell carcinoma.

Hao-Wen Chuang, Li-Han Lin, Dar-Der Ji, Ting-Ying Fu, Herng-Sheng Lee, Yi-Fang Yang, Hsing-Cheng Tseng, Kan-Tai Hsia

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of dental sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 62% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 0 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Hao-Wen ChuangDepartment of Pathology and Laboratory Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Li-Han LinDepartment of Medical Research, MacKay Memorial Hospital, Taipei, Taiwan.
Dar-Der JiDepartment of Tropical Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Ting-Ying FuDepartment of Pathology, Yuan's General Hospital, Kaohsiung, Taiwan.
Herng-Sheng LeeDepartment of Pathology and Laboratory Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Yi-Fang YangDepartment of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Hsing-Cheng TsengDepartment of Pathology and Laboratory Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Kan-Tai HsiaInstitute of Oral Biology, College of Dentistry, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Kaohsiung Veterans General Hospital · TWNational Yang Ming Chiao Tung University · TWMackay Memorial Hospital · TWYuan's General Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/purpose: The serpin peptidase inhibitor, clade E, member 2 (SERPINE2), is upregulated in breast cancer, prostate cancer, and urothelial carcinoma; however, limited information exists regarding its expression in oral cancer. Therefore, this study aimed to analyze the association between SERPINE2 expression and oral squamous cell carcinoma (OSCC) outcomes. Materials and methods: Results: Analysis using online databases revealed higher Conclusion: This study suggests that SERPINE2 may serve as a prognostic biomarker and potential therapeutic target for oral cancer.

Indexed as

Oral cancerProtein expressionSerine protease inhibitorSERPINE2

Identifiers

PMID38303830
PMCPMC10829680
OpenAlexW4380372374

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.